37. (Currently Amended) An isolated polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:~~115~~ 107 ~~or an amino acid sequence comprising an immunogenic portion of SEQ ID NO:115~~.

38. (Original) A fusion protein comprising a polypeptide according to claim 37.

39. (Original) A composition comprising a polypeptide of claim 37 or a fusion protein of claim 38; and a physiologically acceptable carrier.

40. (Original) The composition of claim 39, further comprising a non-specific immune response enhancer.

41. (Original) The composition of claim 40, wherein the non-specific immune response enhancer is an adjuvant.

42 (Original) A method for detecting tuberculosis in a subject, said method comprising the steps of :

(a) obtaining a biological sample comprising peripheral blood mononuclear cells from the subject;

(b) measuring cytokine production by the cells, and

(c) contacting the cells with a polypeptide of claim 37; thereby detecting tuberculosis in a subject.

43. (Original) The method of claim 42, wherein the cytokine is interferon gamma.

44. (Original) The method of claim 42, wherein the peripheral blood mononuclear cells are lymphocytes.

45. (Original) The method of claim 42, wherein the sample is a blood sample.

46. (Original) A method for detecting tuberculosis in a subject, said method comprising the steps of:

(a) obtaining a biological sample from the subject;

(b) contacting the biological sample with a polypeptide of claim 37, and

(c) detecting an antibody in the sample, thereby detecting tuberculosis in the subject.

47. (Original) The method of claim 46, wherein the sample is a blood sample.

48. (Original) A method for detecting tuberculosis in a subject, said method comprising the steps of:

(a) contacting dermal cells of the subject with a polypeptide of claim 37, and

(b) detecting an immune response on the subject's skin, thereby detecting tuberculosis in the subject.

49. (Original) The method of claim 48, wherein the immune response is induration.

50. (Original) A diagnostic kit comprising:

(a) a polypeptide of claim 37; and

(b) apparatus sufficient to contact the polypeptide with the dermal cells of a patient.

51. (Currently Amended) A method of eliciting an immune response in a subject, the method comprising the steps of administering to the subject an immunogenically effective amount of a composition comprising a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:~~115~~ 107 ~~or an amino acid sequence comprising an immunogenic portion of SEQ ID NO:115,~~ and a physiologically acceptable carrier.

52. (Original) The method of claim 51, wherein the composition further comprises a non-specific immune response enhancer.

53. (Original) The method of claim 52, wherein the non-specific immune response enhancer is an adjuvant.

54. (Original) The method of claim 51, wherein the subject is a human.

55. (Original) A vaccine comprising a polypeptide of claim 37 or a fusion protein of claim 38; and a physiologically acceptable carrier.